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H
ydrogels have played an increas-
ingly important role in tissue eng-
ineering.1,2 This is mainly attributed
to the unique properties of hydrogels in-
cluding their high permeability, biodegrad-
ability, tunable physical properties, ability to
provide structural support to bioengineered
tissue constructs, as well as to surface
coat medical implants for improved bio-
compatibility.3,4 Hydrogels can also be
made biofunctional by tethering suitable
growth factors, therapeutic peptides or
drugs molecules for specific tissue-type
applications.5,6 However, these approaches
are limited by short half-life, low binding
efficiency of the drugs or peptides, and
inability to induce long-term therapeutic
effects.7 Hydrogels have also been used as
a platform to support viral, nonviral and
nanoparticle-based gene delivery systems.
Encapsulating such gene delivery vectors
inside hydrogels enables their controlled
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ABSTRACT The objective of this study was to develop an injectable and biocompatible hydrogel which can
efficiently deliver a nanocomplex of graphene oxide (GO) and vascular endothelial growth factor-165 (VEGF)
pro-angiogenic gene for myocardial therapy. For the study, an efficient nonviral gene delivery system using
polyethylenimine (PEI) functionalized GO nanosheets (fGO) complexed with DNAVEGF was formulated and
incorporated in the low-modulus methacrylated gelatin (GelMA) hydrogel to promote controlled and localized
gene therapy. It was hypothesized that the fGOVEGF/GelMA nanocomposite hydrogels can efficiently transfect
myocardial tissues and induce favorable therapeutic effects without invoking cytotoxic effects. To evaluate this
hypothesis, a ratmodel with acute myocardial infarction was used, and the therapeutic hydrogels were injected
intramyocardially in the peri-infarct regions. The secreted VEGF from in vitro transfected cardiomyocytes
demonstrated profound mitotic activities on endothelial cells. A significant increase in myocardial capillary density at the injected peri-infarct region and
reduction in scar area were noted in the infarcted hearts with fGOVEGF/GelMA treatment compared to infarcted hearts treated with untreated sham, GelMA and
DNAVEGF/GelMA groups. Furthermore, the fGOVEGF/GelMA group showed significantly higher (p< 0.05, n= 7) cardiac performance in echocardiography compared
to other groups, 14 days postinjection. In addition, no significant differenceswere noticed between GO/GelMA and non-GO groups in the serum cytokine levels and
quantitative PCR based inflammatory microRNA (miRNA) marker expressions at the injected sites. Collectively, the current findings suggest the feasibility of a
combined hydrogel-based gene therapy system for ischemic heart diseases using nonviral hybrid complex of fGO and DNA.
KEYWORDS: nanomedicine . graphene oxide . injectable hydrogel . gene delivery . myocardial therapy
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delivery at the desired site, preventing unwanted loss
during the transit to the target site and allowing
efficient localized gene therapy with reduced nonspe-
cific spreading to other tissues. Thus, the hydrogel
increases the local retention time of the vector at the
target site, enhancing their chances of getting inter-
nalized by the tissues, which is currently a major
limitation of nonviral nanoparticle-based delivery
systems.8 For example, it has been reported that
alginate hydrogels, containing DNAPEI aggregates,
can enhanceDNAuptake depending on the stiffness of
the gel.9
Hydrogel/nanoparticle-based gene delivery system
can be used to develop advanced bioactive hydrogels
with tissue-specific functionalities. Such a system can
efficiently deliver biotherapeutic molecules in a con-
trolled and localizedmanner, as well as it can utilize the
cell's own machinery for continuous and sustained
production of the therapeutic protein, which is not
possible with bulk protein delivery methods.10,11 Stud-
ies so far have shown that mammalian viral gene
delivery vectors, in combination with hydrogels, can
be used for gene delivery applications.1215 However,
nonviral vectors are clinically more attractive because
of their advantageous features including superior bio-
safety profile, reduced risk of adverse immune reaction
and negligible chance of viral gene integration to the
host genome thereby zero risk of insertional muta-
genesis.16,17 A major disadvantage of nonviral nano-
particles compared to viral systems is poor transfection
efficiency. It has been recently reported that graphene
oxide (GO) nanosheets, a precursor of graphene, can
be efficiently used to deliver genes efficiently when
ionically bonded to cationic polymers such as PEI. PEI is
known as a suitable material for gene transfer because
it binds strongly to DNA, demonstrates proton sponge
effects, and helps in escape of the delivered nucleic
acids from endosomal/lysosomal pathways after cell
internalization. Low molecular weight branched PEI is
also known to have low cytotoxicity and can signifi-
cantly enhance gene delivery efficiency in combina-
tion with GO.1821 This is mainly because of its unique
delivery features such as suitable water dispersibility,
high surface area and aspect ratio, efficient biomolecule
loading and effective cell internalization properties.22,23
In this regard, understanding the therapeutic potential of
a hydrogel-based GO gene delivery system approach
will be beneficial for enabling a range of therapeutic
applications.
In this study, we have developed a low-modulus
GelMA hydrogel, which is a chemically modified form
of native gelatin protein. It was selected because of its
biocompatibility, biodegradability and ability to sup-
port the formation ofmicrovasculature and endothelial
cord formation in vitro and in vivo.2427 This modified
form of denatured collagen has the unique advantages
of both natural and synthetic biomaterials. It retains
the natural RGD-motifs of collagen that mediate cell
attachment, while at the same time preserves the
matrix degradation sites. Additionally, conjugation of
gelatin with methacrylate groups helps to form photo-
polymerizable hydrogels with tunable mechanical and
degradation properties. GelMA is also nontoxic to the
cells when used under the optimal concentrations and
degrees of methacrylation as reported in our earlier
studies.24,25 It has been previously demonstrated that
GelMA can be microengineered to fabricate organized
vasculature in vitro, support microvascular networks
in vivo and support cardiomyocytes in a three-dimen-
sional (3D) microenvironment when blended with
carbon-based nanoparticles such as multiwalled car-
bon nanotubes (CNTs) and GO to generate mechani-
cally strong, electroconductive hydrogels.2832 Here,
GelMA has been impregnated with fGO nanosheets,
for site-specific gene delivery of pro-angiogenic hu-
man vascular endothelial growth factor plasmid DNA
(pDNAVEGF) to damaged cardiac tissues. This injectable
GelMA hydrogel (GG0), carrying fGOVEGF (pDNAVEGF
bound to fGO), was expected to induce a combinatorial
effect, which would facilitate local myocardial neovas-
cularisation at the injected sites, reduce fibrosis and
potentially improve cardiac function in an in vivo
model of acute myocardial infarction (AMI). Figure 1a
illustrates the overall process of in vitro preparation of
GelMA/fGO hydrogel-based hybrid gene delivery sys-
tem and its in vivo localized administration in the heart
for prolonged gene expression and therapy. The in-
jectable GelMA matrix system would not only facilitate
sustained supply of angiogenic genes to the myocar-
dial tissues, but also provide protection of entrapped
DNA against external harsh environment in the beat-
ing heart.
RESULTS AND DISCUSSION
Rheological Properties of the Formulated Hydrogel. To use
the GO/GelMA nanocomposite hydrogels as an inject-
able gene delivery agent, the hydrogel should pass
through surgical needles with minimum efforts. More-
over, after injection, the hydrogel should regain its
mechanical properties and structural stability. To
achieve such a clinically relevant material and facilitate
easy release of fGOVEGF nanosheets, here we used low
degree methacrylation GelMA24 whose injectability
properties were evaluated by viscosity studies using
rheometer and mechanical property analyzer.31,33 The
preliminary investigation using a 22-gauge needle
indicates that all the nanocomposite hydrogel compo-
sitions can be easily injected (Figure 1b (inset)). For
minimally invasive therapies, the hydrogels should
be easily injected near the wound site and should
have sufficient mechanical strength to withstand
in vivo stresses. The ability of fGO/GelMA nanocompo-
sites to flow under mechanical stress was determined
by evaluating the shear thinning capability. In this, a
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constant shear rate was applied to the hydrogel, and
the viscosity was monitored. The decrease in the
viscosity with increasing shear rate indicated that the
nanocomposite hydrogels start flowing under me-
chanical stress. The results indicate that GelMA readily
flows and the mechanical integrity is totally lost as the
viscosity of GelMAwas∼1 Pa. s at the shear rate of 50 s1
(Figure 1b). The addition of fGO significantly increased
the viscosity of the nanocomposite hydrogels at higher
strain rate. This is mainly attributed to the physical
interaction of surface functionalized fGO nanosheets,
with GelMA. Moreover, with the addition of fGO to
GelMA, mechanical strength of the hydrogel network
was enhanced. This was also evident from the increase
in storage modulus (G0) and loss modulus (G00) of
fGO/GelMA network in stress sweep, strain sweep
and frequency sweep experiments compared to Gel-
MA hydrogels (Figure S1). Overall, fGO/GelMA hydro-
gels were easily injectable using surgical needle, and the
addition of fGO significantly reinforces the physical net-
work of the nanocomposite hydrogels.
Characterization of the fGO/DNA Nanocomplex. Our main
hypothesis was that an injectable hydrogel that in-
duces localized gene therapy can significantly improve
myocardial tissue repairing mechanisms. Recent works
in small and large experimental animals have demon-
strated that injectable hydrogels, comprising mainly
native extracellular matrix (ECM), peptide-bound bio-
polymers, or myocardial ECM derived materials, can be
effective in cardiac repair after infarction.3440 This is
Figure 1. Preparation of injectable GG0 hydrogel for AMI therapy. (a) Schematic of stepwise formulation process of
nanobioactive hydrogel and subsequent injection to treat damaged heart with acute myocardial infarction. (1) First, GO
nanosheets are functionalized by amide bond with branched PEI to form cationic fGO. (2) fGO is then surface functionalized
with anionic plasmids (DNAVEGF) to form fGO/DNAVEGF as shown in TEM images. (3) These bioactive hybrids are then
suspended in prepolymer of GelMA hydrogel and UV cross-linked under optimized condition to form (4) injectable fGO/
DNAVEGF carrying GelMA hydrogel (GG0). (5) The latter is then intramyocardially injected in rat heart with acute intramyo-
cardial infarction for local gene delivery of incorporated fGO/DNAVEGF nanocomplexes from GG0 hydrogel. (6) This eventually
exhibits therapeutic effects by promotingmyocardial vasculogenesis, which leads to reduced scar area and improved cardiac
function. (b) Injectability of the developed GO carrying GelMA hydrogel. The viscosity of GO/GelMA nanocomposite
hydrogels was monitored at different shear rates. At low shear rate, both fGO/GelMA and GelMA hydrogels had high
viscosity. However, at higher shear rate, fGO/GelMA and GelMA hydrogels showed decreased viscosity. This indicates that
bothGelMAand fGO/GelMAwere able to flowat higher shear rate andwere easily injectable. The results also indicate that the
addition of surface functionalized fGO to GelMA results in higher viscosity of fGO/GelMA at higher shear rate compared to
GelMA. In other words, fGO reinforces the GelMA hydrogel network. Scale bar: 1 μm.
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because these hydrogels provide cardiac specific struc-
tural support, stimulate local healing mechanism, and
generate bioactive products in the tissue microenvi-
ronment to promote endogenous stem cell homing.
For instance, Ifkovits et al. demonstrated thatmechani-
cally tunable methacrylated hyaluronic acid hydrogels
could be used as an injectable therapeutic biomaterial
for healing of cardiac damage.40 Similarly, it was
postulated that the injectable GelMA hydrogel, com-
prised of natural biochemical cues, will be beneficial to
the ischemic tissue that will potentially support vascu-
lar cell infiltration and endogenous repairmechanisms.
An important criterion while formulating an effi-
cient gene delivery system is to establish a strong
binding of negatively charged DNA to the surfaces of
dispersed cationic fGOnanosheets. Thiswas verified by
transmission electron microscopy (TEM) confirming
uniform nanostructure formation with good dispersiv-
ity, and zeta potential analysis confirming successful
binding of fGO to pDNA (Figure 1a and Figure S2)
following protocol mentioned elsewhere.18 The TEM
micrographs gave morphological evidence that the
untreated GO (∼5 μm) formed homogeneously dis-
persed nanocomplexes of around 3040 nm dimen-
sions after treatment and DNA binding. Zeta potential
analysis at physiological pH 7.4 showed that the un-
treated pristine GO was negatively charged with a zeta
potential of 37 ( 2.4 mV. On the other hand, fGO
showed a highly positive charge (43.0 ( 3.2 mV). The
positive zeta potential value of fGO, upon binding with
the negatively charged pDNA, was reduced. The result-
ing zeta potential values depended on the N/P ratios,
where N/P stands for the ratio of moles of the amine
groups of cationic PEI polymer to those of the DNA
phosphates. N/P ratio of 16, represented as fGO
(16)VEGF, showed highest zeta potential (15.8( 3.5mV),
while at N/P ratio of 4 the charge decreased to negative
value because of overloaded pDNA on fGO surfaces.
This result confirmed the efficient hybrid complex
formation, generated by strong electrostatic interac-
tions of plasmid DNA with fGO nanosheets under
optimized condition as reported elsewhere.18 The
MTS tetrazoliumcytotoxicity assay (Promega,Madison,WI)
of fGO nanocomplexes with embryonic rat cardiomyo-
cytes (H9c2 cells, ATCC) confirmed that fGO (N/P ratios
ranging from 4 to 16) did not invoke statistically sig-
nificant cytotoxic effects on the H9c2 cells compared to
untreated control (Figure S3).
In Vitro Gene Delivery of the Hydrogel. To prepare the
gene delivery system, fGOVEGF was dispersed by vor-
texing in 5% GelMA prepolymer solution and the
prepolymer mixture was photo-cross-linked under op-
timized UV exposure based on previously established
protocol, to form low modulus injectable hydrogel.31
To confirm the release of fGOVEGF nanocomplexes from
the hydrogel, the latter was incubated in phosphate
buffer saline (PBS) solution for 72 h and samples were
collected in regular intervals for agarose gel electro-
phoretic run (Figure S4A). The detected band intensi-
ties for different time points in the gel confirm slow
release of pDNA from GelMA over 72 h, while the
retention of these bands within the wells of the
agarose gel confirms that pDNA was still bound to
the fGO that led to the retardation of electromobility
shift of the bound pDNA, similar to other studies.18,21
This was followed by transfection of the cardiomyo-
cytes with the eluted fGOGFP, carrying green fluores-
cent protein (GFP) gene, or fGOVEGF nanocomplexes
from the GelMA hydrogels, where fGO (16)GFP showed
highest transfection efficiency (Figure S4B). The release
profile of VEGF protein in conditionedmedia (CM) from
fGO (16)VEGF transfected H9c2 cardiomyocytes showed
rapid overexpression of the growth factor in the first 4
days post-transfection as quantified by ELISA, while it
gradually decreased over time by day 14 (Figure S4C).
The data also reconfirmed that GG0 group can signifi-
cantly enhance the gene delivery efficiency compared
to GG (GelMA with free pDNAVEGF) and control G (only
GelMA) groups.
In Vitro Pro-Angiogenic Activities of the Hydrogel. The
bioactivities of the released VEGF by GG0 group were
evaluated in vitro by investigating the proliferative
capacity of the human umbilical vein endothelial cells
(HUVECs) in 3D culture in high degree methacrylated
(∼80%) GelMA hydrogel. MTS assay was used to assess
the proliferation potential of HUVECs treated with CM
(containing VEGF secreted by H9c2) from experimental
samples.41 The results were illustrated as percent
increase in HUVEC proliferation relative to that induced
by CM from unstimulated control group (taken as
100%). As shown in Figure 2a (i), CM from group GG0
showed highest HUVEC proliferation (133.9 ( 6.0%)
compared to GG0 þ Ab and Control (Nontreated)
groups. This is because the overexpressed VEGF from
H9c2 cardiomyocytes was neutralized with antibodies
in GG0 þ Ab group. This proliferation rate was directly
dependent on the amount of the VEGF released which
explains why the treated group demonstrated better
results than nontreated Control and GG0 þ Ab groups.
The lower left panel in Figure 2a (ii) represents the
calcein stained HUVECs in 3D hydrogel in different
groups. Interestingly, the GG0 group also showed
sprouting of HUVECs in the hydrogel which was absent
in other groups. Furthermore, we tested the ability of
CMs from different groups to increase HUVEC wound
healing in a 2D monolayer as demonstrated in other
studies.42 As depicted in Figure 2b (i) and the corre-
sponding representative pictures in lower right panel
in Figure 2b (ii), stimulation of wounded HUVECmono-
layer with CM from GG0 induced significant healing of
wound area (25.6 ( 3.1%) compared to CM from
unstimulated control (5.4 ( 0.7%) and GG0þAb group
(2.5 ( 0.1%). Preincubation of CM with the neutraliz-
ing anti-VEGF antibodies completely hindered VEGF
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induced wound healing, clearly suggesting that che-
motactic signals from VEGF enhances the wound heal-
ing effect. In addition, we explored whether CM can
also induce HUVEC attachment and spreading in a
hydrogel-based channel system within restricted mi-
croenvironment. As described in earlier studies, a
microchannel was formed inside GelMA hydrogel
(high degree methacrylate) and 5  106 HUVECs/mL
Figure 2. In vitro functionalities of GG0 hydrogel onHUVECs. (a i and ii) Proliferation of HUVECs in 3D, grown in the presence of
conditionedmedia (CM, with or without excess of neutralizing anti-VEGF antibodies, Ab: 1mg/mL) from fGO/DNAVEGF/GelMA
transfected H9c2 cardiomyocytes. As control group, CM from nontreated cells was taken. A total of 50 μL of GelMA
prepolymer containing HUVECs were added per well in 96 well-plate. After photo-cross-linking was performed, the cell
containing gels were grown in different CMs for 96h. Cell proliferations were detected by MTS colorimetric assay, while data
(n = 3) presented in graph were normalized by that from control group. Lower left panel shows the representative
photomicrographs of each groupwhereHUVECswere stainedwith calcein dye. Interestingly, HUVEC in GG0 group, apart from
inducing significant proliferation, also demonstrated highly branched tube-like structure formation absent in other groups.
(b i and ii) VEGF-induced migration of HUVECs in wound healing scratch assay. HUVEC monolayer was wounded with cell
scraper and treated with CM from different groups. HUVECs were photographed 12 h post-treatment (lower panel) and the
percentage of scratched area (which was initially free of cells, marked by the white dotted border lines) covered by the
migrated cells were analyzed using ImageJ software. (c iiii) To confirm the potential of CM in combination with GelMA
biomaterial to produce vascularized microstuctures, HUVEC adhesion and migration assay inside GelMA (highly
methacrylated) microchannels was performed. The microchannel was made by needle (200 μm) insertions and photo-
cross-linking. In all groups, HUVECswere suspended in CM from individual groups and seeded inside themicrochannel. After
24 h, photomicrographs of the cell cultured microchannels (lower panel) were taken and analyzed for percentage of
microchannel area covered by adhered andmigrated HUVECs in different experimental groups. Data are expressed as mean
value ( standard deviation (SD). ***P < 0.001, n = 3. Scale bar: 100 μm.
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was grown inside the microchannel in the presence of
CM from different groups.24 Twenty-four hours post
incubationwith CM fromdifferent groups demonstrate
that GG0 group had significantly higher HUVEC attach-
ment and spreading inside the microchannel com-
pared to GG (Figure 2c: 58.5 ( 9.1% vs 26.4 ( 6.4%).
These data confirmed the proliferative, wound healing
and chemotactic effects of VEGF, secreted from GG0,
transfected H9c2 cells.
In Vivo Biocompatibility of fGO/GelMA Hydrogel. Despite
the multiple clinical trials and growing understanding
in cardiovascular research, clinical outcomes of cur-
rently available AMI treatments are deeply influenced
by the post AMI complications, such as inflammation,
stent thrombosis, and other life threatening cardiovas-
cular risk factors.4345 However, promoting vascular-
ization at the injured site to reduce scar formation and
ventricular remodeling has been considered as a viable
treatment method, as observed in several gene ther-
apy studies with viral vectors.13,42,46,47 Through this
study, we intended to develop a biocompatible, non-
viral, controlled gene delivery system using hydrogel-
based cationic GO for AMI therapy. Recently, it has
been demonstrated that GO nanosheets support and
maintain cardiomyocyte functionalities when cultured
in vitro in combination with GelMA hydrogel.31 Taking
advantage of the complementary strengths of GO,
such as relatively high therapeutics loading capacity,
low immunogenicity and high gene delivery effici-
ency,18,21 along with microvascular network support-
ing properties of biodegradable GelMA hydrogel,24,25
here we developed fGOVEGF carrying injectable GelMA
hydrogel and hypothesized that it will be able to
successfully treat AMI in vivo.
As establishing the in vivo biocompatibility of the
formulated GO-based hydrogel is of paramount im-
portance, building on the in vitro results, here we
investigated its inflammatory effects in immunocom-
petent rat model with AMI. The AMI was induced in the
rat models by occlusion of the left anterior descending
coronary artery according to established laboratory
procedures.42 Subsequently, 300 μL of injectable hy-
brid hydrogels was intramyocardially injected at three
different sites in the peri-infarct regions of the heart
(Figure 3a). One group received fGO suspended in 5%
GelMA hydrogel (Gt, n = 3) and the control sham group
received only similar infarction (Gc, n = 3). Seven days
post injection, the formalin fixed paraffin embedded
tissue sections, specifically from the injected regions,
were isolated using laser capture microscopy (LCM).48
This was followed by total RNA extraction for quanti-
tative analysis of four different miRNAs, and detection
of the changes in inflammatory marker expression
compared to untreated control. The miRNAs are small,
noncoding RNA molecules (∼20 nucleotides) present
in introns and exons of noncoding transcripts and
can influence transcriptional regulators, cytokines
and cell surface receptors, thereby affecting the entire
inflammation and immune response system.49,50 The
markers chosen for the study include miRNAs for
proinflammatory role (miR-155), inflammation resolu-
tion role (miR-146a), cardiac aging and function
(miR-34a) and cardioprotective role under apoptotic
condition (miR-145).5153 Quantitative PCR (qPCR)
analysis showed no significant differences between
control and tested animals for all the four miRNAs
analyzed in the study (Figure 3b). Similar results were
obtained by ELISA analysis of pro-inflammatory tumor
necrosis factor R (TNFR) and anti-inflammatory inter-
leukin-10 (IL10) cytokines in blood plasma where no
significant differences were detected in the ratio of
pro/anti-inflammatory cytokines between fGO/GelMA
and control group (Figure 3c). Similar observations
were reported in a recent study by Chowdhury et al.
where the group used dextran functionalized gra-
phene nanoplatelets to assess the hematological and
inflammatory responses in vivo.54 Concomitantly, this
trend was noticed by immunostaining myocardial
tissue sections for TNFR expression (Figure 3d) and
hematoxylin and eosin (H&E) staining (Figure 3e) to
assess acute inflammatory cell infiltration to the
inflammatory site. These data confirmed that the
combination of GO and GelMA did not invoke any
significant toxicity or inflammatory response in vivo.
In Vivo Therapeutic Efficacy in Myocardially Infarcted Rat
Model. After confirming in vivo biocompatibility, we
evaluated the in vivo therapeutic efficacy of the
fGOVEGF based hydrogel in rat model with AMI using
established analysis methods.13,42,46,47 At first, the
gene delivery efficiency was confirmed by fGOLacZ/
GelMA (Figure 4a), where Lac Z was used as the
β-galactosidase coding reporter gene to trace the
protein expression in the transfected heart tissue. This
was confirmed 7 days post operation, by the localized
5-bromo-4-chloro-3-indolyl-β-D-galacto-pyranoside (X-gal)
staining of the myocardial tissue at the injected sites
(Figure 4b,c). The analysis of the X-gal-stained heart
revealed that the LacZ gene expression was mainly
limited to the injected regions surrounding the infarct
region as indicated by the blue X-gal staining. In a
similar way, to achieve highly localized transfection
and angiogenic effects in myocardial tissue, injectable
GelMA carrying fGOVEGF hydrogels were administered
via direct intramyocardial injections at the peri-infarct
region post infarction. It was postulated that the strong
angiogenic effect of the hydrogel would help in pro-
moting vasculogenesis, reducing scar area formation
and improving the heart function in treatment groups.
Toward this goal, a total of 28 immunocompetent rats
were used for in vivo efficacy experiment (Groups:
GG0 = fGOVEGF/GelMA; GG = DNAVEGF/GelMA; G =
GelMA, control = nontreated; n=7). The neovasculature
formation in the peri-infarct area was assessed by
detecting the capillary (Figure 4d) and artery densities
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(Figure 4e). For this, immunohistochemical staining
was performed with antibodies against (platelet en-
dothelial cell adhesion molecule-1) PECAM-1 for iden-
tification of HUVECs and smooth muscle R-actin for
tracing the smoothmuscle cells. As shown in Figure 4d,
significant improvements were observed in capillary
density in the GG0 compared to other groups (148.7 (
21.2/mm2 for GG0, 115.6 ( 8.4/mm2 for GG vs 118.0 (
17.4/mm2 for G, 94.5 ( 15.2 for untreated control,
p< 0.001) analyzed by immunostaining against PECAM
endothelial marker (Figure S5A). This indicates that the
treatment group was able to induce neoangiogenesis
in a paracrine way by releasing VEGF angiogenic
factors to stimulate localized vessel sprouting through
improved paracrine VEGF secretion. However, no
significant differences in arteriole densities (p > 0.05)
were found between the groups as reported in Figure 4e
and Figure S5B with smooth muscle R-actin staining.
Histomorphometric analysis of sirius red stained heart
sections confirmed that the treatment helped to at-
tenuate scar area formation (Figure 5a,b: 19.4 ( 5.8%
for GG0, 28.1( 4.2% for GG vs 27.5( 7.7% for G, 35.6(
4.2% for control, p < 0.01). This data is in support of
earlier studies, which showed that increment in blood
vessel density could support reduction of scar
formation.42,46,47 GG0 group also significantly reduced
the fibrotic area compared to GG as observed from
ventricular infarct area analysis. To investigate if the
reduction in scar formation improved heart function,
the cardiac ejection fraction percentage (EF%) at
Figure 3. In vivo delivery and biocompatibility of injectable fGO carrying GelMA. (a) Schematic of rat heart with AMI.
Photograph (infarcted heart) represents a myocardially infarcted rat heart after causing myocardial infarction by ligation of
left anterior descending artery. Arrows indicate the damaged area in the left ventricular region. Photograph (hydrogel
injection) shows the route of administration via direct intramyocardial delivery of injectable fGO/GelMA hydrogel to the peri-
infarct zones. (b) Representative pictures of peri-infarct region of ventricular tissues 7 days post injection, pre- and postlaser
capture microdissection (LCM) (scale bar: 100 μm). Post-LCM tissue capture and RNA extraction and qPCR based miRNA
expression assays were performed to compare the inflammatory marker-specific miRNA levels in Sham and fGO/GelMA
hydrogel treatedgroups. Thedata in graph represents fold change in expression levels of inflammation-specificmiRNAs,miR-
34a, miR-145, miR-146a and miR-155, between the two groups normalized to RNU48, an abundant and stable human small
nuclear RNAs (snRNAs). No significant differenceswere foundbetween the twogroups confirming the in vivobiocompatibility
of the injected hydrogels. (c) Quantification of blood plasma TNFR and IL10 represented as a ratio of pro and anti-
inflammatory cytokines analyzed by ELISA assay (P < 0.05 = statistically significant, n = 3). (d and e) fGO/GelMAhydrogel does
not invoke any significant difference in pro-inflammatory TNFR expression or white blood cell accumulation in the infarcted
heart compared to sham control. The tissues were either immunostained with TNFR antibody to trace myocardial TNFR
expression (d) or counterstained with H&E (e) to demonstrate histological morphology of orderly arranged myocardial cells
The TNFR immunoreactive cells were stained as dark brown color. Data are expressed asmean value( SD. Scale bar: 200 μm.
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different time periods (day 3 and 14) were monitored
using echocardiography.42,46 EF% of all of the groups
was around 30% (baseline) on day 3 post infarction,
indicating successful AMI in all groups. As presented in
Figure 5c, significant improvement was observed in
EF%ofGG0 groupcompared toother experimental groups
by day 14 (49.4 ( 3.8% for GG0 vs 41.8 ( 4.2% for GG vs
38.4( 6.4% for G vs 36.4( 5.6% for control, p < 0.01).
Figure 4. Confirmation of in vivo gene delivery and pro-angiogenic effects of GG0 hydrogel for AMI therapy. To confirm the
gene delivery potential of formulated hydrogel, fGOLacz/GelMA was injected intramyocardially and expressions of Lac Z
reporter genes in the heart regions were confirmed. (a) Injectable nanobioactive hydrogel. (b) Image of explanted rat heart
showing Lac Z gene expression by X-Gal staining (in blue color) and (c) ventricular tissue section in histology slide at
microscopic level. Quantification of (d) capillaries and (e) arteriole densities in the peri-infarct region, 14 days post injection of
VEGF therapeutic genes in group GG0, GG, G and control (with sham treatment after infarction) by immunohistological
staining of CD31 and smooth muscle R-actin. Data are expressed as mean value ( SD. ANOVA statistical analysis with
Bonferroni post hoc test was performed to determine the significance of the experiments. p < 0.0001; ***P < 0.001, **P < 0.01,
*P<0.05 vs time-matched control (n= 7). P values comparing time-matchedGG0 andGGare indicatedbyψ. Scale bar: 100 μm.
Figure 5. Assessment of in vivo scar areas and cardiac functions of infarcted hearts treated with GG0 hydrogel therapy. (a and
b) Scar area determination by morphometric analysis of the left ventricle in different groups. Representative images of left
ventricle myocardial sections stained with Sirius red show the cardiac fibrosis regions (in red). Sham operated and untreated
infarcted groupwere used as controls. The red area represents ECMdeposition in the scar tissue and the gray area represents
the myocardium. (c) Echocardiographic assessment of cardiac function. For this, heart ejection fraction (EF%) was monitored
at day 2 and 14 post treatment. GG0 showed significantly better EF% than other groups. Data are expressed as mean value(
SD. ANOVA statistical analysis with Bonferroni post-hoc test was performed to determine the significance of the experiments.
p < 0.0001; ***P < 0.001, **P < 0.01, *P < 0.05 vs time-matched control (n = 7). P-values comparing time-matched GG0 and GG
are indicated by ψ.
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CONCLUSIONS
In summary, this newgene-activated hybridmaterial
promises new advancement in AMI therapy to meet
the current clinical needs. The study not only confirms
the in vivo efficacy of the developed hydrogel for post-
AMI therapy but also provides insights into the bio-
compatibility aspects of the system. This strategy is
particularly advantageous compared to widely studied
stem cell therapy whose application is limited mostly
by frequent immune rejections by patients, mainte-
nance of cell viability and retention at the target site,
chances of teratoma formation, along with plethora of
ethical, logistical and technical challenges for cell
isolation and culturing. Moreover the fGO-based hy-
drogel was characterized by scanning electron micro-
scopy, rheological property testing and zeta-potential
analysis. These tests confirmed suitable injectability
and DNA adhesion properties of the fGO-based hydro-
gel formulation. Collectively, the study underscores the
potential of this hydrogel-based, nonviral gene deliv-
ery system which can effectively transfer genes in vivo
as well as induce sustained therapeutic effects. The
formulation is simple and can be easily applied to
plasmid DNA and other nucleic acid delivery systems
for site-specific treatment of different diseases. The
strategy can also limit the number of doses necessary
for long-term effects, compared to the bolus doses of
active protein or drug molecules. Such GO-based gene
delivery approach can also be useful to direct cell
behavior in well-defined 3D hydrogel microenviron-
ment system for advanced tissue engineering applica-
tions. In fact, the delivery of genes using fGO can
function not only as gene complexing agents but also
as structural scaffolds for tissue engineering. This
combination of GO/DNA therapy and tissue engineer-
ing within a single system can be a new strategy for
regenerative medicine.
Although the study findings exemplify the beneficial
effects of low modulus hydrogel-based gene therapy
treatment, further studies are needed to elucidate the
long-term effects of the treatment on heart function. It
is important to investigate whether multiple adminis-
tration of the therapy will invoke further salutary
effects to the infarcted heart. To our advantage, the
GelMA/GO hydrogel based gene delivery system can
be potentially used for codelivery of multiple thera-
peutic genes, bioactive small molecules and peptides.
Slow delivery of combination of such therapeutics
within the same formulation may augment the protein
expression or biofunctional activities of the delivered
materials. Another crucial factor that needs further
studies is to understand the long-term fate of GO in
the host system. Studies in this direction have demon-
strated that polymer functionalized GO remains in the
host body for a long time postadministration, but it
does not significantly invoke the in vivo toxicity.55,56
However, intravenous administration of GO nanoflakes
in mice in high concentration (4 mg/kg) for 5 conse-
cutive days induced mutagenesis.57 Also, Qu et al.
reported GO can increase the level of reactive oxygen
species in macrophages, triggering drastic cell mor-
phologic changes and eventual in vitro necrosis.58
Thus, special considerations have to be given while
optimizing the in vivo dosages and characterizing the
stability of surface functionalized GO nanosheets to
ensure their long-term biocompatibility and safety.
Taken together, this study demonstrated the postu-
lation that this newly formulated gene-active GO/
GelMA hydrogel can take advantage of the unique
features associated with GelMA hydrogel and GO-
based angiogenic gene delivery system to exhibit
enhanced AMI therapeutic efficacy without any sig-
nificant side effects. In particular, the injectable nano-
composite hydrogels induced in vivo beneficial effects
on tissue revascularization at injured site and improved
contractile performance, as corroborated by vasculo-
genesis, scar area analysis and echocardiogram data
examinations. The findings from this study also provide
insight into the biocompatibility properties of this new
therapeutic delivery system for cardiac applications.
MATERIALS AND METHODS
Preparation of Injectable GelMA Hydrogel Carrying GO/DNA Nanocom-
plex. Preparation of Hydrogel. Low methacrylated GelMA was
synthesized as reported earlier.24 Briefly, gelatin at 10% (w/v)
was added in PBS at 50 C and stirred for 1 h to completely
dissolve it. While stirring, methacrylate anhydride (MA) was
added dropwise (0.25% vol %) to the gelatin solution. After
2 h, the reaction was stopped by diluting the solution with PBS.
The diluted mixture was dialyzed against distilled water with a
dialysis membrane (Mw cutoff of 1214 kDa) for 7 days to
remove unreacted MA and salts. The resulting solution was
subsequently frozen in liquid nitrogen and lyophilized to obtain
the final product (∼20% methacrylation).
Preparation of GO/DNA Nanocomplex Formation. GO nano-
sheets were purchased from Nanocs, Inc. and functionalized
to low molecular weight branched PEI using method used
elsewhere.18 Briefly, to bind low molecular weight PEI
(Mw = 1.8 kDa) to the carboxyl groups of GO by 1-ethyl-
3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDC)/
N-hydroxysuccinimide (NHS) coupling, GOs were suspended in
deionized water by sonication, and EDC and NHSwere added to
the GO solution (0.5 mg/mL, 1 mL). Then, 100 μL of triethyla-
mine was added to a PEI solution in deionized water. The PEI
solution was added to the GO prepared (1 mL, 0.5 mg/mL) and
stirred for 24 h. The resulting PEIGO solution was dialyzed
against a 3.5 kDa cutoff dialysis membrane for 48 h to get rid of
the unreacted components. The surface charge of GO, PEIGO
(fGO), and PEIGO/DNA (fGODNA) complexes with different N/P
ratios in PBS buffer were confirmed by zeta potential measure-
ments using Zeta Potential Analyzer (Brookhaven Instruments
Corporation, Holtsville, NY). fGODNA nanocomplexes were pre-
pared at various N/P ratios by the addition of fGO suspensions
to the plasmid DNA solutions in PBS buffer. For the study,
plasmid DNAs, carrying either VEGF165 (Origene) or GFP expres-
sing genes (Promega) driven by a cytomegalo-virus (CMV)
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immediate early promoter, were used as described in earlier
studies.13,42 The final plasmid DNA concentration was adjusted
to 33 μg/mL, and the mixtures were incubated for 30 min to
form the electrostatic nanocomplexes (fGOGFP or fGOVEGF) prior
to measurement of the zeta potential. Transmission electron
microscopy (TEM) was used to obtain the size characterization.
The nanocomplexes were suspended in PBS and analyzed on
CM200 FEG-TEM (Philips, Markham, Ontario, Canada).
Preparation of fGO/GelMA Hydrogel. Lyophilized GelMA
(5 wt %) and photoinitiator (0.25 wt %), 2-hydroxy-1-(4-(hydro-
xyethoxy)phenyl)-2-methyl-1-propanone (Irgacure 2959; CIBA
chemical) were first dissolved in PBS at 80 C for 30 min. Then,
75 μL of this prepolymer solution, along with fGOVEGF (16), was
pipetted into the space between two glass slides separated by a
1 mm spacer and exposed to UV at 6.9 mW/cm2 (wavelength
360480 nm) for 15 s similar to the method used earlier.34 The
compressive modulus and rheological properties of the formed
hydrogel was analyzed using Instron 5524 mechanical analyzer
(Instron, Canton, MA) and AR-G2 Rheometer (TA Instruments)
respectively.33,43
In Vitro Cardiomyocyte Transfection and Biofunctional Analysis. Cyto-
toxicity Assay. First, the in vitro cyototoxicity of the different fGO
formulations was analyzed using MTS cell proliferation assay
(Promega) according the manufacturer's instructions.41 This
was followed by release kinetics study of fGO/DNA nano-
complexes from entrapped GelMA over time. The data con-
firmed rapid release of the entrapped fGO/DNAnanocomplexes
from the GelMA hydrogel in physiological solution as detected
by gel retardation assay. The experiment was performed also to
confirm the successful binding of fGO with DNA molecules
where the DNA bound nanocomplexes show retardation in gel
electrophoresis.
Cardiomyocyte Transfection Study. To optimize the transfec-
tion efficiency, gene delivery efficiency of fGOGFP with three
different N/P ratios (4, 8, 16), control GOand positive control PEI/
DNAGFP groups were studied, where N/P is the ratio of moles of
the amine groups of cationic PEI to those of the phosphate ones
of DNA. To do this, fGOGFP nanocomplexes, eluted from GelMA
hydrogel, were used for the transfection study. Initially, the
H9c2 cells were seeded in 24-well plate at 105 cells/well. Then,
the 72 h eluted samples, adjusted to 2 μg plasmid DNAGFP per
50 μL of fGO/DNAGFP solution, were added to the 250 μL of
serum-free culture medium and the mixture was incubated for
4 h according to earlier established protocol.18 The media was
then replaced with 500 μL of fresh culture medium containing
10% fetal bovine serum (FBS) and grown in 37 C humidified
incubator at 5% CO2. After 4 days, photomicrographs of trans-
fected H9c2 cells using fluorescence microscope (Nikon Eclipse
TE2000-U) were taken under 5 different fields per sample and
percentage transfected cells was calculated. As we obtained
best results with fGOGFP (16) group, we did further studies with
fGOVEGF (16) group. Similar to the above method, the eluted
fGOVEGF (16) were added to H9c2 cells and the conditioned
media (CM) were collected at regular time points for 14 days
and analyzed for VEGF ELISA (R&D Systems) following manu-
facturer's protocol.
HUVECCell Proliferation Assay. To investigate the bioactivity
of released VEGF on HUVECs, Day 4 CMs from three groups
(control = nontreated, GG0 = fGOVEGF/GelMA, GG0 þ Ab = GG0
with VEGF Antibody) were collected. In GG0 þ Ab, the CM was
preincubated with anti-VEGF neutralizing antibody (R&D Sys-
tems; 1 mg/mL) for 30 min, before adding to the cells. For the
HUVEC cell proliferation assay in 3D, 50 μL of 3 106 HUVEC/mL
of GelMA prepolymers was added per well in triplicate for each
sample in 96-well plates and photo-cross-linked using standard
method.28 After 12 h of culturing in serum starved condition
(1% FBS), the cells were washed twice with PBS and 200 μL of
conditionedmedia fromdifferent groupswith andwithout anti-
VEGF antibody supplementation was added to the correspond-
ing set of wells. After 96 h, the absorbance was measured at
490 nmusing cell proliferation assay (Cell Titer 96 Aqueous Non-
Radioactive Assay, Promega) in a plate reader. In a separate group,
the cells were stained with calcein dye to track the viable cells.
HUVEC scratch assay. To check the wound healing potential
of released VEGF, HUVECs were seeded into 24-well plates and
grown to confluency. After 24 h of serum starvation (1% FBS),
lesions were made in the monolayer using cell scraper.42 Cells
were rinsed with PBS, and then incubated with the H9c2 CM
from different experimental groups (GG0 , control, GG0 þ Ab) for
24 h. Cells were fixed with 4% paraformaldehyde after 24 h and
the number of cells which had moved across the starting
scratched lines were measured for all groups. Three fields were
analyzed for each well.
HUVEC Migration through Microchannel. To demonstrate
the potential of CM for GelMA based vascularised tissue en-
gineering, HUVECs were seeded into a perfusable GelMAmicro-
channel. For this, a block of GelMA was photopolymerized
containing a syringe needle, which when removed contained
a 200 μm diameter perfusable channel as shown in Figure 3.
Rhodamine-bound dextran (200 kDa) was perfused through the
microchannel to demonstrate the ability to create perfusable,
microfluidic channels within the GelMA microstructures. This
was followed by addition of 5  106 HUVEC/mL of CM media
from different groups into the microchannel and the cultures
were grown for 24 h in normal cell culture condition. Then, the
cells were stained with calcein dye, stained, photographed
under fluorescence microscope, and analyzed by ImageJ for
percentage of channel area covered by HUVEC.
Induction of Myocardial Infarction in Rat Model for in Vivo Studies.
Immunocompetent Lewis rats (200250 g, Charles River, QC)
were used in an in vivo myocardial infarction model according
to established protocols.13,42 All procedures were in compliance
with the Guide for the Care and Use of Laboratory Animals (NIH
publication No. 85-23) and the Guide to the Care and Use of
Experimental Animals of the Canadian Council on Animal Care.
Briefly, Lewis rats were anesthetized using isoflurane followed
and mechanical ventilation (Harvard Ventilator, Canada) using
catheter at 80 breaths/min. Anesthesia wasmaintained with 3%
isoflurane. The left coronary artery was ligated 2 mm from its
origin with polypropylene suture. Fifteenminutes post ligations
of the arteries, the rats with acute myocardial injections were
subjected to treatments with different formulations. For the
experiments, 300 μL of injectable GO carrying GelMA hydrogel
with different formulations was used. Three equal left ventri-
cular direct intramyocardial injections, 100 μL each, were
injected at the peri-infarct regions.
Investigating the in Vivo Biocompatibility of fGO/GelMA Hydrogel. To
confirm the biocompatibility of the developed hydrogel, ani-
mals were divided into 2 groups. One group of animals, after
myocardial infarction, were injected with 300 μL of fGO/GelMA
containing 0.5 mg fGO/mL GelMA (Gt, n = 3) and the other
control group received only PBS solution (Gc, n = 3). Seven days
post injection, the animals were sacrificed. The excised hearts
were immediately soaked in cold saline to remove excess blood
from the ventricles and fixed in neutral-buffered 4% formalin.
The samples were embedded in paraffin and sectioned at
56 μm thick for histological (H&E) and immunostaining
(myocardial TNFR staining) analysis.
To enable quantitative PCR (qPCR) basedmicroRNA analysis
selected ventricular region laser capture microdissection (LCM)
instrument was used. First, a rectangular areas measuring
∼5000 μm2 in the peri-infarct regions of the heart sections
were carefully dissected out using PALM Laser system (Carl
Zeiss) from each group.48 The captured tissues were immedi-
ately lysed in Trizol (Invitrogen). Then the tissue was processed
for miRNA isolation. To do this, total RNA was extracted from all
the samples using Trizol RNAeasy mini (Qiagen) kit protocols.
Total RNA was reverse transcribed using Taqman miRNA RT
(reverse transcription) kit, muliplexed for all the miRNA RT
primers included in the study. The resultant complementary
DNAs (cDNAs) were subjected to a preamplification PCR using
multiplexed miRNA probes. The amplified products were then
used for the final qPCR for the individual miRNAs. Relative
expression of each miRNA was calculated using ΔΔCt method,
normalized to RNU48 (an abundant and stable small nuclear
RNA) expression.48
In addition, the cardiac blood was also collected to investi-
gate the plasma inflammatory cytokine profile using rat IL10
and TNFR ELISA kit (SA Biosciences) using manufacturer's
protocol.
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Assessment of in Vivo Therapeutic Efficacy of the Developed GO/DNA
Based Hydrogel. Confirmation of in Vivo Gene Delivery. To confirm
the in vivo gene delivery to the myocardial tissue using GelMA
based GO gene delivery system, 3 animals were intramyocar-
dially injected with fGOLacZ/GelMA hydrogel. In vivo Lac Z
expression at the injection sites was detected using X-gal
(bromo-chloro-indolyl-galactopyranoside) by sacrificing the an-
imals 7 days post administration as previously described.42
Confirmation of Functional Efficacy. To perform this, myo-
cardially infarcted rats were divided into 4 groups. The G group
(n = 7) received 300 μL of only GelMA, GG group (n = 7) received
DNAVEGF/GelMA and GG0 group (n = 7) received fGOVEGF/GelMA
(N/P ratio 16), where the last 2 groups received 20 μg of
plasmids per animal following the protocol mentioned above.
The control group received 300 μL of PBS only. To understand
the functional efficacy of the different treatment groups, ani-
mals were analyzed by (a) immunohistochemistry to examine
neovascularisation, (b) histological analysis to detect scar area,
and (c) echocardiography to examine cardiac performance
2 weeks post treatment.
(a) Immunohistochemistry to detect neovascularisation:
Capillary and arteriole densities in the peri-infarct regions were
quantified by tracing neovascularized regions. Immunohisto-
chemical staining was performedwith anti-PECAM1 (Santa Cruz
Biotechnology, Santa Cruz, CA) and smooth muscle R- actin
antibodies to trace the vascularized myocardial tissues in the
peri-infarct regions. For capillary density measurement, five
fields in the peri-infarct regions were imaged and capillaries
with less than 10 μm diameter were counted. The capillary
densities were quantified as the mean of total PECAM-positive
microvessels per mm2 area using three different fields of the
per-infarct tissue regions per animal. In a similar way, arteriole
densities were quantified as the mean of total smooth muscle R-
actin positivemicrovessels permm2area for eachgroupof animals.
(b) Histological analysis of scar areas: Paraffin embedded
5 μm thickness samples were deparaffinized and stained with
collagen-specific Sirius Red dye for detection and quantification
of fibrosis areas (in red) in the ventricular region using ImageJ-
1.41 software as reported earlier.59
(c) Echocardiography for cardiac performance evaluation:
Transthoracic echocardiography studies were performed using
echocardiographic instrument (Sonosite, Seattle, WA) after
sedating the animals with isoflurane. Left ventricular ejection
fractions (EF) were calculated from the echocardiogram in all
the four groups 2 days (baseline) and 2 weeks post infarction.59
Statistical Analysis. Quantitative variables are presented as
mean ( standard deviation (SD) from independent experi-
ments as described in the figure legends. Statistics were
performed using two-way and/or one-way analysis of variance
(ANOVA) by Bonferroni's multiple comparison post-hoc test. All
statistical analyses were performed with Prism 5 (GraphPad
Software). P-value <0.05 was considered significant.
Conflict of Interest: The authors declare no competing
financial interest.
Supporting Information Available: Rheological properties of
the hybrid injectable GO/GelMA hydrogel, photo-cross-linkable
nature of hydrogel and its biocompatibility, TEM images of GO
nanocomplexes and zeta potential, cytotoxicity analysis with
cells, GO/DNA release kinetics from hydrogel and the transfec-
tion efficiency, quantification of secretory VEGF protein over-
expression, in vivo immunohistological and histological staining
pictures. This material is available free of charge via the Internet
at http://pubs.acs.org.
Acknowledgment. The authors acknowledge funding from
the Presidential Early Career Award for Scientists and Engineers
(PECASE), National Institutes of Health (HL092836, AR057837,
DE021468, DE019024, EB012597, HL099073, EB008392) and
MIT- Portugal Program (MPP-09Call-Langer-47). D.S.-T. acknowl-
edges funding support from Collaborative Health Research
Project, Canada and National Sciences & Engineering Research
Council of Canada (NSERC) Strategic Project Grants from Cana-
da. A.P. acknowledges postdoctoral award from FRQS (Fonds de
rechercheduQuébec - Santé), Quebec, Canada. A.H. acknowledges
the Postdoctoral award from Natural Sciences and Engineering
Research Council of Canada.
REFERENCES AND NOTES
1. Slaughter, B. V.; Khurshid, S. S.; Fisher, O. Z.; Khademhosseini,
A.; Peppas, N. A. Hydrogels in Regenerative Medicine. Adv.
Mater. 2009, 21, 3307–3329.
2. Langer, R.; Vacanti, J. P. Tissue Engineering. Science 1993,
260, 920–926.
3. Khademhosseini, A.; Vacanti, J. P.; Langer, R. Progress in
Tissue Engineering. Sci. Am. 2009, 300, 64–71.
4. Khademhosseini, A.; Langer, R.; Borenstein, J.; Vacanti, J. P.
Microscale Technologies for Tissue Engineering and Biol-
ogy. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 2480–2487.
5. Schukur, L.; Zorlutuna, P.; Cha, J.M.; Bae, H.; Khademhosseini,
A. Directed Differentiation of Size-Controlled Embryoid
Bodies towards Endothelial and Cardiac Lineages in
RGD-Modified Poly(ethylene glycol) Hydrogels. Adv. Health-
care Mater. 2013, 2, 195–205.
6. Khetan, S.; Guvendiren, M.; Legant, W. R.; Cohen, D. M.;
Chen, C. S.; Burdick, J. A. Degradation-Mediated Cellular
Traction Directs Stem Cell Fate in Covalently Crosslinked
Three-Dimensional Hydrogels.Nat. Mater. 2013, 12, 458–465.
7. Ashley, G. W.; Henise, J.; Reid, R.; Santi, D. V. Hydrogel Drug
Delivery System with Predictable and Tunable Drug Re-
lease and Degradation Rates. Proc. Natl. Acad. Sci. U.S.A.
2013, 110, 2318–2323.
8. Jang, J. H.; Schaffer, D. V.; Shea, L. D. Engineering Bioma-
terial Systems to Enhance Viral Vector Gene Delivery. Mol.
Ther. 2011, 19, 1407–1415.
9. Kong, H. J.; Liu, J.; Riddle, K.; Matsumoto, T.; Leach, K.;
Mooney, D. J. Non-viral Gene Delivery Regulated by Stiff-
ness of Cell Adhesion Substrates. Nat. Mater. 2005, 4, 460–
464.
10. Cam, C.; Segura, T. Matrix-based Gene Delivery for Tissue
Repair. Curr. Opin. Biotechnol. 2013, 24, 855–863.
11. Holladay, C.; Keeney, M.; Greiser, U.; Murphy, M.; O'Brien, T.;
Pandit, A. A Matrix Reservoir for Improved Control of Non-
viral Gene Delivery. J. Controlled Release 2009, 136, 220–
225.
12. Schek, R. M.; Hollister, S. J.; Krebsbach, P. H. Delivery and
Protection of Adenoviruses using Biocompatible Hydro-
gels for Localized Gene Therapy. Mol. Ther. 2004, 9, 130–
138.
13. Paul, A.; Shao, W.; Abbasi, S.; Shum-Tim, D.; Prakash, S.
PAMAM Dendrimer-Baculovirus Nanocomplex for Micro-
encapsulated Adipose Stem Cell-Gene Therapy: In Vitro
and in Vivo Functional Assessment. Mol. Pharmaceutics
2012, 9, 2479–2488.
14. Hu, W. W.; Wang, Z.; Hollister, S. J.; Krebsbach, P. H.
Localized Viral Vector Delivery to Enhance in Situ Regen-
erative Gene Therapy. Gene Ther. 2007, 14, 891–901.
15. Paul, A.; Elias, C. B.; Shum-Tim, D.; Prakash, S. Bioactive
Baculovirus Nanohybrids for Stent Based Rapid Vascular
Re-endothelialization. Sci. Rep. 2013, 3, 2366.
16. Curtin, C. M.; Cunniffe, G. M.; Lyons, F. G.; Bessho, K.;
Dickson, G. R.; Duffy, G. P.; O'Brien, F. J. Innovative Collagen
Nano-hydroxyapatite Scaffolds Offer a Highly Efficient
Non-viral Gene Delivery Platform for Stem Cell-Mediated
Bone Formation. Adv. Mater. 2012, 24, 749–754.
17. Yin, L.; Song, Z.; Kim, K. H.; Zheng, N.; Gabrielson, N. P.;
Cheng, J. Non-viral Gene Delivery via Membrane-
penetrating, Mannose-Targeting Supramolecular Self-
Assembled Nanocomplexes. Adv. Mater. 2013, 25, 3063–
3070.
18. Kim, H.; Namgung, R.; Singha, K.; Oh, I. K.; Kim, W. J.
Graphene oxide-Polyethylenimine Nanoconstruct as a
Gene Delivery Vector and Bioimaging Tool. Bioconjugate
Chem. 2011, 22, 2558–2567.
19. Feng, L.; Zhang, S.; Liu, Z. Graphene Based Gene Transfec-
tion. Nanoscale 2011, 3, 1252–1257.
20. Yin, D.; Li, Y.; Lin, H.; Guo, B.; Du, Y.; Li, X.; Jia, H.; Zhao, X.;
Tang, J.; Zhang, L. Functional Graphene Oxide as a Plasmid-
based Stat3 siRNA Carrier Inhibits Mouse Malignant
A
RTIC
LE
PAUL ET AL. VOL. 8 ’ NO. 8 ’ 8050–8062 ’ 2014
www.acsnano.org
8061
Melanoma Growth in Vivo. Nanotechnology 2013, 24,
105102.
21. Kim, H.; Kim, W. J. Photothermally Controlled Gene
Delivery by Reduced Graphene Oxide-Polyethylenimine
Nanocomposite. Small 2014, 10, 117–126.
22. Bitounis, D.; Ali-Boucetta, H.; Hong, B. H.; Min, D. H.;
Kostarelos, K. Prospects and Challenges of Graphene in
Biomedical Applications. Adv. Mater. 2013, 25, 2258–2268.
23. Feng, L.; Yang, X.; Shi, X.; Tan, X.; Peng, R.; Wang, J.; Liu, Z. Poly-
ethylene Glycol and Polyethylenimine Dual-functionalized
Nano-graphene Oxide for Photothermally Enhanced Gene
Delivery. Small 2013, 9, 1989–1997.
24. Nichol, J. W.; Koshy, S. T.; Bae, H.; Hwang, C.M.; Yamanlar, S.;
Khademhosseini, A. Cell-Laden Microengineered Gelatin
Methacrylate Hydrogels. Biomaterials 2010, 31, 5536–
5544.
25. Chen, Y. C.; Lin, R. Z.; Qi, H.; Yang, Y.; Bae, H.; Melero-Martin,
J. M.; Khademhosseini, A. Functional Human Vascular
Network Generated in Photocrosslinkable Gelatin Metha-
crylate Hydrogels. Adv. Funct. Mater. 2012, 22, 2027–2039.
26. Lin, R. Z.; Chen, Y. C.; Moreno-Luna, R.; Khademhosseini, A.;
Melero-Martin, J. M. Transdermal Regulation of Vascular
Network Bioengineering using a Photopolymerizable
Methacrylated Gelatin Hydrogel. Biomaterials 2013, 34,
6785–6796.
27. Nikkhah, M.; Eshak, N.; Zorlutuna, P.; Annabi, N.; Castello,
M.; Kim, K.; Dolatshahi-Pirouz, A.; Edalat, F.; Bae, H.; Yang, Y.;
et al. Directed Endothelial Cell Morphogenesis in Micro-
patterned Gelatin Methacrylate Hydrogels. Biomaterials
2012, 33, 9009–9018.
28. Shin, S. R.; Bae, H.; Cha, J. M.; Mun, J. Y.; Chen, Y. C.; Tekin, H.;
Shin, H.; Farshchi, S.; Dokmeci, M. R.; Tang, S.; et al. Carbon
Nanotube Reinforced Hybrid Microgels as Scaffold Materi-
als for Cell Encapsulation. ACS Nano 2012, 6, 362–372.
29. Shin, S. R.; Jung, S. M.; Zalabany, M.; Kim, K.; Zorlutuna, P.;
Kim, S. B.; Nikkhah, M.; Khabiry, M.; Azize, M.; Kong, J.; et al.
Carbon-Nanotube Embedded Hydrogel Sheets for Engi-
neering Cardiac Constructs and Bioactuators. ACS Nano
2013, 7, 2369–2380.
30. Ramon-Azcon, J.; Ahadian, S.; Estili, M.; Liang, X.; Ostrovidov,
S.; Kaji, H.; Shiku, H.; Ramalingam, M.; Nakajima, K.; Sakka, Y.;
et al. Dielectrophoretically Aligned Carbon Nanotubes to
Control Electrical and Mechanical Properties of Hydrogels
toFabricateContractileMuscleMyofibers.Adv.Mater.2013,
25, 4028–4034.
31. Shin, S. R.; Aghaei-Ghareh-Bolagh, B.; Dang, T. T.; Topkaya,
S. N.; Gao, X.; Yang, S. Y.; Jung, S. M.; Oh, J. H.; Dokmeci,
M. R.; Tang, X. S.; et al. Cell-Laden Microengineered and
Mechanically Tunable Hybrid Hydrogels of Gelatin and
Graphene Oxide. Adv. Mater. 2013, 25, 6385–6391.
32. Cha, C.; Shin, S. R.; Gao, X.; Annabi, N.; Dokmeci, M. R.; Tang,
X. S.; Khademhosseini, A. Controlling Mechanical Proper-
ties of Cell-Laden Hydrogels by Covalent Incorporation of
Graphene Oxide. Small 2014, 10, 514–523.
33. Mihaila, S. M.; Gaharwar, A. K.; Reis, R. L.; Marques, A. P.;
Gomes, M. E.; Khademhosseini, A. Photocrosslinkable
Kappa-carrageenan Hydrogels for Tissue Engineering
Applications. Adv. Healthcare Mater. 2013, 2, 895–907.
34. Seif-Naraghi, S. B.; Singelyn, J. M.; Salvatore, M. A.; Osborn,
K. G.; Wang, J. J.; Sampat, U.; Kwan, O. L.; Strachan, G. M.;
Wong, J.; Schup-Magoffin, P. J. Safety and Efficacy of
an Injectable Extracellular Matrix Hydrogel for Treating
Myocardial Infarction. Sci. Transl. Med. 2013, 5, 173ra25.
35. Liu, Z.; Wang, H.; Wang, Y.; Lin, Q.; Yao, A.; Cao, F.; Li, D.;
Zhou, J.; Duan, C.; Du, Z.; et al. The Influence of Chitosan
Hydrogel on Stem Cell Engraftment, Survival and Homing
in the Ischemic Myocardial Microenvironment. Biomater-
ials 2012, 33, 3093–3106.
36. Shuman, J. A.; Zurcher, J. R.; Sapp, A. A.; Burdick, J. A.;
Gorman, R. C.; Gorman, J. H., 3rd; Goldsmith, E. C.; Spinale,
F. G. Localized Targeting of Biomaterials Following Myo-
cardial Infarction: A Foundation to Build on. Trends Cardi-
ovasc. Med. 2013, 23, 301–311.
37. MacArthur, J. W., Jr.; Purcell, B. P.; Shudo, Y.; Cohen,
J. E.; Fairman, A.; Trubelja, A.; Patel, J.; Hsiao, P.; Yang, E.;
Lloyd, K.; et al. Sustained Release of Engineered Stromal
Cell-derived Factor 1-alpha from Injectable Hydrogels
Effectively Recruits Endothelial Progenitor Cells and Pre-
serves Ventricular Function After Myocardial Infarction.
Circulation 2013, 128, S79–S86.
38. Johnson, T. D.; Christman, K. L. Injectable Hydrogel Thera-
pies and Their Delivery Strategies for Treating Myocardial
Infarction. Expert Opin. Drug Delivery 2013, 10, 59–72.
39. Tous, E.; Purcell, B.; Ifkovits, J. L.; Burdick, J. A. Injectable
Acellular Hydrogels for Cardiac Repair. J. Cardiovasc.
Transl. Res. 2011, 4, 528–542.
40. Ifkovits, J. L.; Tous, E.; Minakawa, M.; Morita, M.; Robb, J. D.;
Koomalsingh, K. J.; Gorman, J. H., 3rd; Gorman, R. C.;
Burdick, J. A. Injectable Hydrogel Properties Influence
Infarct Expansion and Extent of Postinfarction Left Ven-
tricular Remodeling in an Ovine Model. Proc. Natl. Acad.
Sci. U.S.A. 2010, 107, 11507–11512.
41. Paul, A.; Shao, W.; Shum-Tim, D.; Prakash, S. The Attenua-
tion of Restenosis Following Arterial Gene Transfer Using
Carbon Nanotube Coated Stent Incorporating TAT/DNA-
(Ang1þVegf) Nanoparticles. Biomaterials 2012, 33, 7655–
7664.
42. Paul, A.; Binsalamah, Z. M.; Khan, A. A.; Abbasia, S.; Elias,
C. B.; Shum-Tim, D.; Prakash, S. A Nanobiohybrid Complex
of Recombinant Baculovirus and Tat/DNA Nanoparticles
for Delivery of Ang-1 Transgene in Myocardial Infarction
Therapy. Biomaterials 2011, 32, 8304–8318.
43. Gerczuk, P. Z.; Kloner, R. A. AnUpdate on Cardioprotection:
A Review of the Latest Adjunctive Therapies To Limit
Myocardial Infarction Size in Clinical Trials. J. Am. Coll.
Cardiol. 2012, 59, 969–978.
44. Windecker, S.; Bax, J. J.; Myat, A.; Stone, G. W.; Marber, M. S.
Future Treatment Strategies in ST-segment Elevation
Myocardial Infarction. Lancet 2013, 382, 644–657.
45. Nabel, E. G.; Braunwald, E. A Tale of Coronary Artery
Disease and Myocardial Infarction. N. Engl. J. Med. 2012,
366, 54–63.
46. Takahashi, K.; Ito, Y.; Morikawa, M.; Kobune, M.; Huang, J.;
Tsukamoto, M.; Sasaki, K.; Nakamura, K.; Dehari, H.; Ikeda,
K.; et al. Adenoviral-delivered Angiopoietin-1 Reduces the
Infarction and Attenuates the Progression of Cardiac
Dysfunction in the Rat Model of Acute Myocardial Infarc-
tion. Mol. Ther. 2003, 8, 584–592.
47. Tao, Z.; Chen, B.; Tan, X.; Zhao, Y.; Wang, L.; Zhu, T.; Cao, K.;
Yang, Z.; Kan, Y. W.; Su, H. Coexpression of VEGF and
Angiopoietin-1 Promotes Angiogenesis and Cardiomyo-
cyte Proliferation Reduces Apoptosis in Porcine Myocar-
dial Infarction (MI) Heart. Proc. Natl. Acad. Sci. U.S.A. 2011,
108, 2064–2069.
48. Moore, C. S.; Rao, V. T.; Durafourt, B. A.; Bedell, B. J.; Ludwin,
S. K.; Bar-Or, A.; Antel, J. P. miR-155 as a Multiple Sclerosis-
Relevant Regulator of Myeloid Cell Polarization. Ann.
Neurol. 2013, 74, 709–720.
49. O'Connell, R. M.; Rao, D. S.; Baltimore, D. microRNA Regula-
tion of Inflammatory Responses. Annu. Rev. Immunol.
2012, 30, 295–312.
50. Dai, R.; Ahmed, S. A. MicroRNA, a New Paradigm for
Understanding Immunoregulation, Inflammation, and
Autoimmune Diseases. Transl. Res. 2011, 157, 163–179.
51. Nazari-Jahantigh, M.; Wei, Y.; Schober, A. The role of
microRNAs in arterial remodelling. Thromb. Haemost.
2012, 107, 611–618.
52. Boon, R. A.; Iekushi, K.; Lechner, S.; Seeger, T.; Fischer, A.;
Heydt, S.; Kaluza, D.; Treguer, K.; Carmona, G.; Bonauer, A.;
et al. MicroRNA-34a Regulates Cardiac Ageing and Func-
tion. Nature 2013, 495, 107–110.
53. Li, R.; Yan, G.; Li, Q.; Sun, H.; Hu, Y.; Sun, J.; Xu, B. MicroRNA-
145 Protects Cardiomyocytes against Hydrogen Peroxide
(H2O2)-induced Apoptosis Through Targeting the Mito-
chondria Apoptotic Pathway. PLoS One 2012, 7, e44907.
54. Chowdhury, S. M.; Kanakia, S.; Toussaint, J. D.; Frame, M. D.;
Dewar, A. M.; Shroyer, K. R.; Moore, W.; Sitharaman, B.
In vitroHematological and in Vivo Vasoactivity Assessment
of Dextran Functionalized Graphene. Sci. Rep 2013, 3,
2584.
A
RTIC
LE
PAUL ET AL. VOL. 8 ’ NO. 8 ’ 8050–8062 ’ 2014
www.acsnano.org
8062
55. Yang, K.; Gong, H.; Shi, X.; Wan, J.; Zhang, Y.; Liu, Z. In vivo
Biodistribution and Toxicology of Functionalized Nano-
Graphene Oxide in Mice After Oral and Intraperitoneal
Administration. Biomaterials 2013, 34, 2787–2795.
56. Yang, K.; Wan, J.; Zhang, S.; Zhang, Y.; Lee, S. T.; Liu, Z.
In Vivo Pharmacokinetics, Long-Term Biodistribution, and
Toxicology of PEGylated Graphene in Mice. ACS Nano
2011, 5, 516–522.
57. Liu, Y.; Luo, Y.; Wu, J.; Wang, Y.; Yang, X.; Yang, R.; Wang, B.;
Yang, J.; Zhang, N. GrapheneOxide Can Induce in Vitro and
in Vivo Mutagenesis. Sci. Rep. 2013, 3, 3469.
58. Qu, G.; Liu, S.; Zhang, S.; Wang, L.; Wang, X.; Sun, B.; Yin, N.;
Gao, X.; Xia, T.; Chen, J. J.; Jiang, G. B. Graphene Oxide
Induces Toll-like Receptor 4 (TLR4)-Dependent Necrosis in
Macrophages. ACS Nano 2013, 7, 5732–5745.
59. Paul, A.; Srivastava, S.; Chen, G.; Shum-Tim, D.; Prakash, S.
Functional Assessment of Adipose Stem Cells for Xeno-
transplantation using Myocardial Infarction Immunocom-
petent Models: Comparison with BoneMarrow Stem Cells.
Cell Biochem. Biophys. 2013, 67, 263–273.
A
RTIC
LE
